EFS in patients with adverse-risk karyotypes after exclusion of patients with either abnl(17p) or −5/5q−. EFS in patients with adverse-risk karyotypes classified by MK, CK, or monosomy 7 after exclusion of AML with either of the 2 marker lesions abnl(17p) or −5/5q−. (A) EFS at 2 years was 53% (95% CI, 30%-76%) in 19 patients with MK⁺ AML compared with 48% (95% CI, 36%-60%) in 76 patients with MK⁻ AML. (B) EFS at 2 years was 47% (95% CI, 31%-63%) in 38 patients with CK⁺ AML compared with 51% (95% CI, 37%-75%) in 57 patients with CK⁻ AML. (C) EFS at 2 years was 49% (95% CI, 22%-76%) in 14 patients with MK⁺ AML with monosomy 7 with compared with 57% (95% CI, 28%-86%) in 12 patients with MK⁻ AML with monosomy 7.